Menu Close
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Clinical
    • Critical Care
    • Procedures
    • COVID-19
  • Practice Management
    • Quality
    • Public Policy
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Learning Portal
    • The Hospital Leader Blog
    • From SHM
    • SIG Spotlight
    • Chapter Spotlight

An Official Publication of
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Clinical
    • Critical Care
    • Procedures
    • COVID-19
  • Practice Management
    • Quality
    • Public Policy
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Learning Portal
    • The Hospital Leader Blog
    • From SHM
    • SIG Spotlight
    • Chapter Spotlight

Heart Failure

  • 1
    News

    ICMs detect serious arrhythmias in high-risk post-MI patients: SMART-MI

    August 27, 2021

    In patients with modestly reduced left ventricular ejection fraction after MI, implantable monitors detect many times more arrhythmias than usual care, the SMART-MI trial showed.

  • 1
    News

    EMPEROR-Preserved: Empagliflozin scores HFpEF breakthrough

    August 27, 2021

    Empagliflozin is the first treatment to produce an unequivocal, hard-endpoint benefit in patients with heart failure with preserved ejection fraction, a practice-changing result.

  • 1
    News

    SGLT2 inhibitor use rising in patients with DKD

    August 23, 2021

    Use of SGLT2 inhibitors in patients with type 2 diabetes rose sharply in 2019 and early 2020. GLP-1 RA use also showed recent gains.

  • News

    Empagliflozin gets HFrEF approval from FDA

    August 19, 2021

    The SGLT2 inhibitor empagliflozin (Jardiance) becomes the second agent from this class to get a heart failure indication regardless of diabetes status.

  • News

    Docs fight back after losing hospital privileges, patients, and income

    August 10, 2021

    Physicians in St. Louis lost their hospital privileges when the hospital entered into an exclusive contract with other physicians. They’re losing patients and money.

  • 1
    News

    Myocarditis tied to COVID-19 shots more common than reported?

    August 6, 2021

    Myocarditis may develop rapidly in younger people, mostly after the second dose, while pericarditis affects older adults after the first or second dose. Both remain rare, new results show.

  • 1
    News

    ESC heart failure guideline to integrate bounty of new meds

    July 29, 2021

    It has a simple answer to a seemingly complex issue: how to merge the newly approved with mainstay drug therapies. And it conditionally okays meds in a group long without guideline-directed options.

  • Article

    Rising meth-related heart failure admissions a ‘crisis,’ costly for society

    July 23, 2021

    ‘They’re not going to die from it overnight, but it will damage the heart slowly,’ a researcher said. Meth-related HF admissions exploded in the western United States over a recent decade.

  • News

    New details of myocarditis linked to COVID vaccines

    July 2, 2021

    Further details from multiple cases of myocarditis linked to the Pfizer and Moderna mRNA COVID vaccines have been described in recent papers in the medical literature.

  • 1
    News

    FDA to add myocarditis warning to mRNA COVID-19 vaccines

    June 24, 2021

    But a CDC advisory panel, where the FDA made the announcement, still strongly backs the vaccines’ benefits, which outweigh the rare risk for heart inflammation.

Previous1 2 3 4 5 … 19Next
  • About The Hospitalist
  • Contact Us
  • The Editors
  • Editorial Board
  • Authors
  • Publishing Opportunities
  • Subscribe
  • Advertise
  • Copyright © 2000-2023 by the Society of Hospital Medicine and related companies. All rights reserved. ISSN 1553-085X
  • Privacy Policy
  • Terms and Conditions
  • SHM’s DE&I Statement
  • Cookie Preferences